Outcomes | Participants identified from study sites | Participants referred from other sources | p |
---|---|---|---|
Underwent an on-site viral load test, n (%) | 95/95 (100) | 104/104 (100) | – |
Viral load test result, n (%) | Â | Â | Â |
 Positive | 71/95 (74.7) | 85/104 (81.7) | 0.536a |
 Negative | 23/95 (24.2) | 18/104 (17.3) |  |
 Invalid | 1/95 (1.1) | 1/104 (1.0) |  |
Had cirrhosis, n (%) | 8/71 (11.3) | 7/85 (8.2)b | 0.522c |
Received DAA-based treatment, n (%) | 71/71 (100) | 81/85 (95.3)d | 0.126a |
Referred to the state hospital for specialized care, n (%) | 0/71 (100) | 2/85 (2.4)e | 0.501a |
Received DAA-based treatment on the same day as the viral load test, n (%) | 43/71 (60.6) | 65/81 (80.2) | 0.008c |
Completed treatment, n (%) | 61/71 (85.9) | 55/81 (67.9) | 0.009c |
Reasons of incomplete treatment, n (%) | Â | Â | Â |
 Imprisonment | 1/10 (10.0) | 1/26 (3.6) | 0.484a |
 LTFU | 9/10 (90.0) | 25/26 (96.2) |  |
Had an SVR test result, n (%) | 61/61 (100) | 54/55 (98.2) | 0.474a |
Achieved SVR, n (%) | 56/61 (91.8) | 50/54 (92.6) | > 0.95a |